Impact of introduction of angiotensin II antagonist on the antihypertensive utilization in Taiwan

Tong Lu Lin, Yea Huei Kao Yang, Chao Hsiun Tang, Huei Mei Wu, Hui Wen Cheng

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

This study aimed to evaluate the long term impact of a new pharmacological class antihypertensive medicine-angiotensin II antagonist (AIIA) on the clinical utilization of existing antihypertensive medications in Taiwan. Claims data of medical service and prescriptions of antihypertensive agents during 1997 to 2002 were obtained from National Health Insurance Research Database (NHIRD). Gross growth of defined daily dose (DDD) and prescription numbers, clinical market share and prescription market share analysis, market penetration time and DDDs/prescription were used to assess AIIA's impact on the angiotensin converting enzyme inhibitors (ACEI), β-Blockers, calcium channel blockers (CCB) and other miscellaneous antihypertensive agents. CCB had the highest gross growth of DDDs and prescription at 117.1 and 3.4 million increments, respectively. Analysis of clinical market share revealed that the introduction of AIIA had the most significant impact to the clinical utilization of miscellaneous antihypertensive agents (5.5%) and a moderate impact on both B-blockers (4.5%) and ACEI (4.1%). Whereas the greatest impact of prescription market share was observed with miscellaneous antihypertensive agents (-6.5%), a moderate impact with ACEI (-2.3%) and a very minor impact with β-blockers (0.9%). CCB, however, had a positive clinical market share (+3.9%) and prescription market share (+2.4%) correlated with AIIA. AIIA utilization implicated by relative growth strength for the clinical market share and prescription market share at medical center, regional hospital, district hospital and primary care clinic were 4.95:3.77:2.77:1 and 5.28:4.17:2.94:1, respectively. The introduction of AIIA did not affect the decreasing trend of clinical utilization of miscellaneous antihypertensive agents and β-blockers since this downtrend started before AIIA introduction. On the other hand, there was increasing usage of CCB and AIIA to control hypertension in Taiwan. Medical centers were the early adaptors for AIIA and played an important role in the utilization diffusion of AIIA.

Original languageEnglish
Pages (from-to)21-29
Number of pages9
JournalJournal of Food and Drug Analysis
Volume16
Issue number4
Publication statusPublished - Aug 2008

Fingerprint

antihypertensive agents
angiotensin II
market share
Taiwan
Angiotensin II
Antihypertensive Agents
antagonists
Prescriptions
calcium channel blockers
Calcium Channel Blockers
Angiotensin-Converting Enzyme Inhibitors
Dichlorodiphenyldichloroethane
Growth
health insurance
market analysis
District Hospitals
National Health Programs
hypertension
drug therapy
Primary Health Care

Keywords

  • β-blocker
  • Angiotensin converting enzyme inhibitor (ACEI)
  • Angiotensin II antagonist (AIIA)
  • Calcium channel blocker (CCB)
  • Defined daily dose (DDD)
  • Drug utilization
  • Market share

ASJC Scopus subject areas

  • Food Science
  • Pharmacology

Cite this

Impact of introduction of angiotensin II antagonist on the antihypertensive utilization in Taiwan. / Lin, Tong Lu; Yang, Yea Huei Kao; Tang, Chao Hsiun; Wu, Huei Mei; Cheng, Hui Wen.

In: Journal of Food and Drug Analysis, Vol. 16, No. 4, 08.2008, p. 21-29.

Research output: Contribution to journalArticle

@article{0a9aea1b437b4d1fa155b1dbfe36b537,
title = "Impact of introduction of angiotensin II antagonist on the antihypertensive utilization in Taiwan",
abstract = "This study aimed to evaluate the long term impact of a new pharmacological class antihypertensive medicine-angiotensin II antagonist (AIIA) on the clinical utilization of existing antihypertensive medications in Taiwan. Claims data of medical service and prescriptions of antihypertensive agents during 1997 to 2002 were obtained from National Health Insurance Research Database (NHIRD). Gross growth of defined daily dose (DDD) and prescription numbers, clinical market share and prescription market share analysis, market penetration time and DDDs/prescription were used to assess AIIA's impact on the angiotensin converting enzyme inhibitors (ACEI), β-Blockers, calcium channel blockers (CCB) and other miscellaneous antihypertensive agents. CCB had the highest gross growth of DDDs and prescription at 117.1 and 3.4 million increments, respectively. Analysis of clinical market share revealed that the introduction of AIIA had the most significant impact to the clinical utilization of miscellaneous antihypertensive agents (5.5{\%}) and a moderate impact on both B-blockers (4.5{\%}) and ACEI (4.1{\%}). Whereas the greatest impact of prescription market share was observed with miscellaneous antihypertensive agents (-6.5{\%}), a moderate impact with ACEI (-2.3{\%}) and a very minor impact with β-blockers (0.9{\%}). CCB, however, had a positive clinical market share (+3.9{\%}) and prescription market share (+2.4{\%}) correlated with AIIA. AIIA utilization implicated by relative growth strength for the clinical market share and prescription market share at medical center, regional hospital, district hospital and primary care clinic were 4.95:3.77:2.77:1 and 5.28:4.17:2.94:1, respectively. The introduction of AIIA did not affect the decreasing trend of clinical utilization of miscellaneous antihypertensive agents and β-blockers since this downtrend started before AIIA introduction. On the other hand, there was increasing usage of CCB and AIIA to control hypertension in Taiwan. Medical centers were the early adaptors for AIIA and played an important role in the utilization diffusion of AIIA.",
keywords = "β-blocker, Angiotensin converting enzyme inhibitor (ACEI), Angiotensin II antagonist (AIIA), Calcium channel blocker (CCB), Defined daily dose (DDD), Drug utilization, Market share",
author = "Lin, {Tong Lu} and Yang, {Yea Huei Kao} and Tang, {Chao Hsiun} and Wu, {Huei Mei} and Cheng, {Hui Wen}",
year = "2008",
month = "8",
language = "English",
volume = "16",
pages = "21--29",
journal = "Journal of Food and Drug Analysis",
issn = "1021-9498",
publisher = "Elsevier Taiwan LLC",
number = "4",

}

TY - JOUR

T1 - Impact of introduction of angiotensin II antagonist on the antihypertensive utilization in Taiwan

AU - Lin, Tong Lu

AU - Yang, Yea Huei Kao

AU - Tang, Chao Hsiun

AU - Wu, Huei Mei

AU - Cheng, Hui Wen

PY - 2008/8

Y1 - 2008/8

N2 - This study aimed to evaluate the long term impact of a new pharmacological class antihypertensive medicine-angiotensin II antagonist (AIIA) on the clinical utilization of existing antihypertensive medications in Taiwan. Claims data of medical service and prescriptions of antihypertensive agents during 1997 to 2002 were obtained from National Health Insurance Research Database (NHIRD). Gross growth of defined daily dose (DDD) and prescription numbers, clinical market share and prescription market share analysis, market penetration time and DDDs/prescription were used to assess AIIA's impact on the angiotensin converting enzyme inhibitors (ACEI), β-Blockers, calcium channel blockers (CCB) and other miscellaneous antihypertensive agents. CCB had the highest gross growth of DDDs and prescription at 117.1 and 3.4 million increments, respectively. Analysis of clinical market share revealed that the introduction of AIIA had the most significant impact to the clinical utilization of miscellaneous antihypertensive agents (5.5%) and a moderate impact on both B-blockers (4.5%) and ACEI (4.1%). Whereas the greatest impact of prescription market share was observed with miscellaneous antihypertensive agents (-6.5%), a moderate impact with ACEI (-2.3%) and a very minor impact with β-blockers (0.9%). CCB, however, had a positive clinical market share (+3.9%) and prescription market share (+2.4%) correlated with AIIA. AIIA utilization implicated by relative growth strength for the clinical market share and prescription market share at medical center, regional hospital, district hospital and primary care clinic were 4.95:3.77:2.77:1 and 5.28:4.17:2.94:1, respectively. The introduction of AIIA did not affect the decreasing trend of clinical utilization of miscellaneous antihypertensive agents and β-blockers since this downtrend started before AIIA introduction. On the other hand, there was increasing usage of CCB and AIIA to control hypertension in Taiwan. Medical centers were the early adaptors for AIIA and played an important role in the utilization diffusion of AIIA.

AB - This study aimed to evaluate the long term impact of a new pharmacological class antihypertensive medicine-angiotensin II antagonist (AIIA) on the clinical utilization of existing antihypertensive medications in Taiwan. Claims data of medical service and prescriptions of antihypertensive agents during 1997 to 2002 were obtained from National Health Insurance Research Database (NHIRD). Gross growth of defined daily dose (DDD) and prescription numbers, clinical market share and prescription market share analysis, market penetration time and DDDs/prescription were used to assess AIIA's impact on the angiotensin converting enzyme inhibitors (ACEI), β-Blockers, calcium channel blockers (CCB) and other miscellaneous antihypertensive agents. CCB had the highest gross growth of DDDs and prescription at 117.1 and 3.4 million increments, respectively. Analysis of clinical market share revealed that the introduction of AIIA had the most significant impact to the clinical utilization of miscellaneous antihypertensive agents (5.5%) and a moderate impact on both B-blockers (4.5%) and ACEI (4.1%). Whereas the greatest impact of prescription market share was observed with miscellaneous antihypertensive agents (-6.5%), a moderate impact with ACEI (-2.3%) and a very minor impact with β-blockers (0.9%). CCB, however, had a positive clinical market share (+3.9%) and prescription market share (+2.4%) correlated with AIIA. AIIA utilization implicated by relative growth strength for the clinical market share and prescription market share at medical center, regional hospital, district hospital and primary care clinic were 4.95:3.77:2.77:1 and 5.28:4.17:2.94:1, respectively. The introduction of AIIA did not affect the decreasing trend of clinical utilization of miscellaneous antihypertensive agents and β-blockers since this downtrend started before AIIA introduction. On the other hand, there was increasing usage of CCB and AIIA to control hypertension in Taiwan. Medical centers were the early adaptors for AIIA and played an important role in the utilization diffusion of AIIA.

KW - β-blocker

KW - Angiotensin converting enzyme inhibitor (ACEI)

KW - Angiotensin II antagonist (AIIA)

KW - Calcium channel blocker (CCB)

KW - Defined daily dose (DDD)

KW - Drug utilization

KW - Market share

UR - http://www.scopus.com/inward/record.url?scp=55049117019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55049117019&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 21

EP - 29

JO - Journal of Food and Drug Analysis

JF - Journal of Food and Drug Analysis

SN - 1021-9498

IS - 4

ER -